Frankfurt-based cannabis company Bloomwell Group GmbH announced on Tuesday that is combining its existing brands and operations to form Germany’s largest digital platform for medical cannabis. The new centralized digital platform, which comes as Germany transitions to a post-prohibition cannabis economy, creates a one-stop marketplace for medical marijuana patients, physicians, pharmacies and suppliers under the Bloomwell brand name.
Under the initiative, Bloomwell Group is uniting and further developing the subsidiary brands Grüne Brise, the first and largest marketplace for cannabis pharmacies, and Algea Care, Europe’s largest cannabis telemedicine platform. Together, the operations will form Germany’s largest digital medical cannabis platform based on the number of participating users.
Germany flag with cannabis leaves as a border.
“By combining these well-respected businesses with a doctors-operated system enabling the scaling of treatment and a data-backed pharmaceutical logistics system that connects with leading wholesalers,” the company wrote in a statement, “Bloomwell now serves as the centralized digital infrastructure for medical cannabis distribution, therapy and dispensing, including speedy delivery services that are the first of its kind in Germany and bring prescriptions to patients’ homes within 24 hours.”
Bloomwell’s announcement comes only weeks after CanG, landmark legislation that ends Germany’s prohibition of cannabis, went into effect on April 1. In addition to allowing adults to possess and use marijuana, the new law reclassifies cannabis as a non-narcotic and enables doctors to prescribe the plant as they would any prescription medication.
Number Of Medical Cannabis Patients In Germany Climbing
Since CanG went into effect, the number of medical cannabis patients in Germany has climbed dramatically, with Bloomwell Group seeing a 1,000% increase in monthly new patients in April 2024, compared with the average number of new patients during each of the previous 12 months.
Niklas Kouparanis, Bloomwell Group CEO and co-founder, says that “Germany’s reclassification of medical cannabis as a non-narcotic is a major catalyst for market development. Still, progressive policies alone won’t enable the sector to reach its full potential and serve all medical patients in need.”
“We’re digitizing the entire medical cannabis experience and industry, seamlessly connecting patients, physicians, pharmacies and wholesalers, and offering 24-hour prescription delivery,” Kouparanis writes in an email. “Our aim is to make the medical cannabis prescription process as accessible and transparent as possible, and ensure supply meets demand. We’re scaling our platform to be able to service 100,000 patients monthly and will be ready for the millions of medical cannabis patients that Germany is projected to have in the years following reclassification.”
The integration of Bloomwell’s operations, which includes a smartphone app, provides full access to a network of doctors and medical cannabis suppliers. By combining all aspects of the medical cannabis experience in one place, the company says the new unified platform will provide transparency, reliability and effectiveness in the care of medical cannabis patients.
“We want to ease any burdens for medical cannabis patients and remove bottlenecks faced by doctors and pharmacies,” Kouparanis said in a statement from Bloomwell Group. “Our platform is designed to minimize administrative tasks for physicians, and through our central IT infrastructure, we are enabling an increasing number of pharmacies to effectively supply patients with medical cannabis, with fewer logistical and administrative hurdles. For patients, we are making treatment with medical cannabis a more seamless process than ever before with an app, as well as with completely digitized e-prescriptions.”
“Bloomwell Group can now be considered a centralized hub for all those who want to make medical cannabis treatment as effective, simple and reliable as possible,” he continued. “This digital and scalable platform will shape the future of medical cannabis in Germany, as well as throughout Europe.”
H/T: www.forbes.com
